Berkshire Hathaway Doubles Down on Homebuilders, Makes Alphabet Top 10 Holding
Berkshire Hathaway Q2 holdings shows new names and changes to old positions. Here's the list of changes and the top 10 holdings.
Read original at benzingaStocks · News reference
DaVita Enters Value-Based Care Agreement With Humana Medicare Advantage To Provide Care To Members With Chronic Kidney Disease Stages 3B–5
Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the greatest impact.As
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 25, 2026, 10:12 AM
- Checked
- Aug 25, 2026, 10:12 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
TD Cowen Upgrades DaVita to Buy, Lowers Price Target to $220
TD Cowen analyst Ryan Langston upgrades DaVita (NYSE:DVA) from Hold to Buy and lowers the price target from $201 to $220.
Read original at benzingaTruist Securities Maintains Hold on DaVita, Lowers Price Target to $215
Truist Securities analyst David Macdonald maintains DaVita (NYSE:DVA) with a Hold and lowers the price target from $250 to $215.
Read original at benzingaMark Cuban Wants Investors Out of Health Insurers. That’s Tough If You Own These ETFs
Mark Cuban is urging funds to divest from major health insurers. Here’s how broad-market ETFs remain exposed to the companies he’s targeting.
Read original at benzingaMark Cuban Urges Investors to Pressure Health Insurers Over Healthcare Costs: ‘You Can Make a Difference’
Mark Cuban urged investors to pressure health insurers over healthcare costs, calling for funds to divest their stakes.
Read original at benzingaJP Morgan Maintains Neutral on Humana, Raises Price Target to $393
JP Morgan analyst Lisa Gill maintains Humana (NYSE:HUM) with a Neutral and raises the price target from $316 to $393.
Read original at benzinga